Promoter holding
64.27%
BL
Biogenomics Limited - Due diligence report
A 360° intelligence report on Biogenomics: trust score, financial health, credit view, compliance, directors, growth and distress signals - …
Full Due-Diligence Report + Documents
- Unlock all financial figures & 5-year trends
- Full trust, health & credit-risk scores
- Director details, charges & MCA documents
₹700
₹349
50% off
New user
Or enjoy up to 50% off with credits
View credit packages
Company Credits – Starter
- One credit unlocks this full due-diligence report
- Use across any company’s report, anytime
- Credits valid for 12 months
Choose your own credit amount
View credit packages
Biogenomics — 360° Intelligence Report
Generated from MCA filings & public records69/100
Trust Score
Moderate
Biogenomics is assessed as Moderate with a Trust Score of 69/100. Biogenomics is an active public limited indian non-government company incorporated in 2002, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It reported a loss in its latest filed year. Based on MCA filings and public records, it currently shows a moderate compliance risk and moderate financial risk profile.
Report generated on 06 Jul 2026 from the latest processed filings. Biogenomics Limited snapshot & full profile →
Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.
02
Score Card
Higher is safer · rule-based & explainableTrust ScoreModerate
69/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreModerate
62/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreModerate
60/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreModerate
50/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreCaution Indicated
45/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
85/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
90/100
Early-warning signals - higher means fewer warnings.
03
Financial Intelligence Dashboard
Standalone · 5 filed year(s)Unlock the full 5-year financial dashboard with charts and year-wise figures.
Get full accessScores and observations on this page are already computed from the real filings - only the underlying figures are locked.
04
Credit & Compliance Intelligence
Why the scores are what they are
Credit Risk Score: 50/100 Moderate
- Negative operating earnings - debt service depends on external support.
- No open charges - unencumbered balance sheet.
- Working-capital cover adequate.
Charges position: 0 open (-) · 3 satisfied (8.70 cr).
Banking relationships (from registered charges)
| Lender | Charges | Amount |
|---|---|---|
| Standard Chartered Bank | 1 | 48.0 cr |
| Icici Bank Limited | 1 | 48.0 cr |
| U.C.O. Bank | 1 | 48.0 cr |
Compliance Score: 62/100 Moderate
- Company status is Active as per MCA.
- Annual filings current (balance sheet Mar 2025).
- Flagged by authority: EPFO.
- Delayed payments to MSME suppliers disclosed (6 disclosure(s)).
- 4 active GST registration(s).
05
Director Intelligence
Stability score: 45/100| Name | DIN / PAN | Designation | Appointed | Tenure | DIN status |
|---|---|---|---|---|---|
| PUSHKAR JAUHARI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| RAJESH SHASHIKANT DALAL | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| RAJIV MALIK | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| NAMIT RUSTAGI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| AMMAR ABDULLAH HAMAD AL ALI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| ARCHANA RAJESH KRISHNAN | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Imran Jamiluddin Shaikh | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| ALI ABDULLAH ALI AL AAMRI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| MOHAMMED HAMDAN SAIF AL RUBAIE | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| ABHISHEK VILAS DESHPANDE | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Shilpa Rakesh Shetty | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
- 11 directors on the board.
- AMMAR ABDULLAH HAMAD AL ALI has DIN status "Deactivated due to non-filing of DIR-3 KYC".
- 2 director exit(s) in the last 3 years.
- Average tenure above 5 years.
Director & KMP remuneration (FY 2024)
| Name | Designation | Total remuneration |
|---|---|---|
| A K Sharma | Managing Director | 2.4 cr |
| R Mehta | Whole-time Director | 1.6 cr |
| S Iyer | CFO | 95.0 L |
Remuneration is disclosed in the latest annual return. Unlock full report
06
Ownership & Group Intelligence
As per FY 2024 annual returnPublic / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
Mb Holdings Mauritius Limited
Subsidiaries
-
Group entities
-
Capital events
12 allotment(s) · 2 transfer(s)
Promoters hold a dominant controlling stake - exact percentages are part of the full report.
| Group entity | Relationship | % held |
|---|---|---|
| Biogenomics International Spc | Subsidiary Company | 74.00% |
| Mb Holdings Mauritius Limited | Holding Company | 74.00% |
Key managerial personnel: ARCHANA RAJESH KRISHNAN (Whole-time director) · ABHISHEK VILAS DESHPANDE (CFO)
Full shareholding pattern, group structure & capital events →
07
Risk Intelligence Center
Growth 85 · Distress 90
Growth signals & trust indicators
Revenue acceleration: +38% over 4 year(s).
Latest year revenue grew 1.42.
EPFO headcount growing - hiring signal.
Operating for 24+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
MSME payment delays disclosed - latest outstanding 24,181.52.
08
Stakeholder Verdicts
Vendor · Banker · InvestorVendor due diligence72/100
Favourable indicators
Suitability as a supplier / customer counterparty.
- Check the compliance flags before onboarding.
- No distress signals on file.
- Financial filings available for verification.
Banker assessment56/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
- Debt capacity assessed from filed statements.
- No existing security registered - first-charge position available.
- Compliance gaps should be priced into terms.
Investor view72/100
Positive growth indicators
Growth quality and scalability through an investor lens.
- 3 growth signal(s) detected.
- Margin and return trends computable from filings.
- Management churn warrants questions.
09
MCA Filings & Events Timeline
Latest 15 events24 Sep 2025
Last AGM held
Annual general meeting
20 Aug 2025
Charge satisfied
Standard Chartered Bank
01 Jul 2025
Director appointed
RAJIV MALIK (Additional Director)
31 Mar 2025
Latest balance sheet
Filed with ROC
23 Sep 2024
Director ceased
Imran Jamiluddin Shaikh
20 Aug 2024
Director appointed
Imran Jamiluddin Shaikh (Nominee Director)
08 Apr 2024
Director appointed
Shilpa Rakesh Shetty (Company Secretary)
31 Mar 2024
Share transfer (FY 2024)
1064961.00000000 shares to Rajmal Parakh
Share transfer (FY 2024)
417570.00000000 shares to SULAIMAN MOHAMED HAMED AL HARTHY
Director ceased
RAJESH SHASHIKANT DALAL
21 Mar 2024
Charge created
Standard Chartered Bank - 3.98 cr
08 Dec 2023
Director appointed
RAJESH SHASHIKANT DALAL (Director)
05 Jul 2022
Director ceased
PUSHKAR JAUHARI
Director ceased
ALI ABDULLAH ALI AL AAMRI
Director ceased
MOHAMMED HAMDAN SAIF AL RUBAIE
10
Key Observations
Auto-generated from the data aboveRevenue grew 2.1x over the last 4 financial year(s).
Net profit margin moved from 24% to 0.86.
Net worth is positive.
11 active director(s) / partner(s); review board churn before relying on management continuity.
4 active GST registration(s) indicate ongoing business operations.
All 3 registered charge(s) stand satisfied - past borrowings repaid.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2024 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 12 security allotment(s) - amounts available in the full report.
5 overseas direct investment(s) (ODI) on record - international footprint.
| Company | CIN | Location |
|---|---|---|
| Zenon Lifesciences Private Limited | U36912GJ2015PTC082749 | Sanand, Gujarat, India |
| Maha Avtar Health Care Private Limited | U24232DL2008PTC178277 | Delhi, Delhi, India |
| Aquigen Bio | U74999PN2018PTC176298 | Mulshi, Maharashtra, India |
| Accretion Pharmaceuticals Limited | L21004GJ2023PLC146545 | Sanand, Gujarat, India |
| Gujarat Liqui Pharmacaps Private Limited | U24231GJ1995PTC027963 | Vadodara, Gujarat, India |
| Elanta Agro Private Limited | U24120PN2012PTC142774 | Sangli, Maharashtra, India |
| Polo Pharmaceuticals Private Limited | U24239HP1995PTC017140 | Himachal Pradesh, Himachal Pradesh, India |
| Middle Mist Pharmaceuticals Private Limited | U33100TN2015PTC101687 | Chennai, Tamil Nadu, India |
12
Who Uses This Report
CA · CS · Banker · Investor · VendorChartered Accountants (CA)
Verify Biogenomics before audits and certifications: compliance score 62/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.
Company Secretaries (CS)
Track statutory health of Biogenomics: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.
Bankers & NBFCs
Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 50/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.
Investors & Analysts
Investor view: Positive growth indicators. Growth score 85/100, margin trends, ownership structure and peer set for Biogenomics - screening before a deeper diligence.
Vendors & Procurement Teams
Vendor verdict: Favourable indicators. Trust score 69/100, distress signals and MSME payment-delay disclosures - know whether Biogenomics pays its suppliers before you extend credit terms.
Lawyers & Compliance Teams
Litigation footprint (no cases on record), regulatory flags, charge documents trail and director networks for Biogenomics - groundwork for KYC, onboarding and disputes.
13
Frequently Asked Questions
Is Biogenomics an active company?
Biogenomics has MCA status “Active” with a compliance score of 62/100 (Moderate).
Is Biogenomics financially healthy?
Biogenomics has a Financial Health Score of 60/100 (Moderate) based on its filed financial statements.
Should I do business with Biogenomics?
Its overall Trust Score is 69/100 (Moderate). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.
Who controls Biogenomics?
The ultimate holding entity is Mb Holdings Mauritius Limited. 11 active director(s) are on record.
Does Biogenomics have loans or charges against its assets?
No open charges - all 3 registered charge(s) stand satisfied, indicating past borrowings were repaid.
Is Biogenomics up to date with its ROC filings?
Annual filings current (balance sheet Mar 2025). Overall compliance score: 62/100 (Moderate).
Is it risky to lend to Biogenomics?
Its Credit Risk Score is 50/100 (Moderate). Banker verdict: Mixed indicators - deeper appraisal suggested.
Disclaimer: This report is generated automatically from MCA filings and public records as available
in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the
underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are
not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice.
Verify from official sources and consult a qualified professional before any business, lending or investment decision.
If you represent this company and believe any information is inaccurate or outdated,
report it here and we will review promptly.
